AVEED (testosterone undecanoate) by Verity Pharmaceuticals is androgens, including testosterone and dihydrotestosterone (dht) are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. Approved for male hypogonadism. First approved in 2014.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AVEED (testosterone undecanoate) is an intramuscular injectable androgen replacement therapy approved in 2014 for male hypogonadism. It restores testosterone and DHT to normal physiological levels, supporting development and maintenance of male sex characteristics and secondary sexual function. The drug is also being investigated for indications including erectile dysfunction, obesity, prediabetes, and nonalcoholic steatohepatitis.
With only 757 Part D claims and LOE arriving May 2027, AVEED operates as a niche product with minimal team scale and declining commercial momentum.
androgens, including testosterone and dihydrotestosterone (DHT) are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of prostate, seminal vesicles, penis, and scrotum; the…
Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight/Obese Men With T2DM or Prediabetes and Hypogonadism
Trial of Testosterone Undecanoate for Optimizing Performance During Military Operations
Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men
Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men
Study to Compare DITEST to Testosterone Undecanoate in Adult Men With Hypogonadism
Worked on AVEED at Verity Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in ~2 years — expect lifecycle management and generic defense hiring
AVEED currently shows zero linked job openings and minimal commercial footprint ($1M Part D spending, 757 claims). Working on this product offers limited career growth opportunity due to niche positioning, LOE approaching in 1.1 years, and minimal team infrastructure.